Literature DB >> 2153799

Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A.

A Rego1, R Vargas, B Wroblewska, M L Foegh, P W Ramwell.   

Abstract

The effect of Cyclosporin A (CsA) on vascular vasomotor responses was determined in two isolated tissue preparations. The first preparation was the rat mesenteric vascular bed which was constricted by phenylephrine (EC80) and perfused with CsA (8.32 x 10(-8) to 8.32 x 10(-6) M). Vasodilation responses to acetylcholine, bradykinin and the calcium ionophore, A23187, were impaired, as was the response to sodium nitroprusside at high CsA concentrations. Indomethacin had no effect suggesting that the CsA effect is unrelated to the synthesis of cyclooxygenase products. In the second preparation, thoracic aortic rings from rats treated with CsA (5-10 and 20-50 mg/kg/daily for 3 and 1 weeks, respectively) were used. Aorta rings precontracted by phenylephrine (EC80) also showed impaired responses to both endothelium-dependent (acetylcholine) and endothelium-independent (sodium nitroprusside) vasodilators. Furthermore, a marked decrease of the guanosine 3',5'-cyclic monophosphate (cGMP) content in aortic preparations was found to accompany the in vivo effect of CsA on relaxation. In addition, exposure of aortic rings to CsA (8.32 x 10(-8) to 8.32 x 10(-6) M) in vitro, also inhibited markedly the cGMP response induced by acetylcholine or sodium nitroprusside. This effect of CsA was not modified by isobutyl methylxanthine, a phosphodiesterase inhibitor. We conclude that CsA acts directly on the vascular smooth muscle; and speculate that CsA may compromise the response to vasodilators by inhibiting cGMP formation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153799

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration.

Authors:  Cristian A Amador; Jean-Philippe Bertocchio; Gwennan Andre-Gregoire; Sandrine Placier; Jean-Paul Duong Van Huyen; Soumaya El Moghrabi; Stefan Berger; David G Warnock; Christos Chatziantoniou; Iris Z Jaffe; Philippe Rieu; Frederic Jaisser
Journal:  Kidney Int       Date:  2016-02       Impact factor: 10.612

2.  Acute effects of cyclosporin and cremophor EL on endothelial function and vascular smooth muscle in the isolated rat heart.

Authors:  P Mankad; J Spatenka; Z Slavik; G O'Neil; A Chester; M Yacoub
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

3.  Coronary vasomotor responses in cyclosporine-treated piglets.

Authors:  G Berkenboom; D Brékine; P Unger; B Gulbis; J Fontaine
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

Review 4.  Hypertension after renal transplantation.

Authors:  V Schwenger; M Zeier; E Ritz
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

5.  Lack of inhibition by cyclosporin in the Schultz-Dale reaction.

Authors:  E S Assem; C I Ezeamuzie; B Y Wan; Y Ayalew
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

6.  Cyclosporin treatment does not impair the release of nitric oxide in human coronary arteries.

Authors:  G S O'Neil; A H Chester; S Kushwaha; M Rose; S Tadjkarimi; M H Yacoub
Journal:  Br Heart J       Date:  1991-09

7.  Chronic treatment with cyclosporine A in New Zealand rabbit: aortic and erectile tissue alterations.

Authors:  E Ragazzi; C Meggiato; A Chinellato; G Italiano; F Pagano; A Calabrò
Journal:  Urol Res       Date:  1996

8.  Vascular mechanisms of cyclosporin-induced hypertension in the rat.

Authors:  J B Roullet; H Xue; D A McCarron; S Holcomb; W M Bennett
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.